Equilis Equenza T (Canada)

This page contains information on Equilis Equenza T for veterinary use.
The information provided typically includes the following:
  • Equilis Equenza T Indications
  • Warnings and cautions for Equilis Equenza T
  • Direction and dosage information for Equilis Equenza T

Equilis Equenza T

This treatment applies to the following species:
Manufacturer: Intervet

EQUINE INFLUENZA VACCINE, KILLED VIRUS, PURIFIED SUBUNITS - TETANUS TOXOID

Description

Equilis® Equenza T is a liquid sub-unit vaccine, containing 3 isolates of equine influenza virus, A equi 1 (Prague), A equi 2 (Newmarket 1/93; "American" subtype) and A equi 2 (Newmarket/2/93; "European" subtype), combined with tetanus toxoid. The virus vaccine fraction is inactivated by use of beta-propiolactone and the combined product contains Quil A as an adjuvant.

Equilis Equenza T Indications For Use

As an aid in the prevention of equine influenza caused by strains of Influenza A/equine1 and A/equine2 and tetanus caused by Clostridium tetani.

Equilis Equenza T Dosage And Administration

Inject the contents of 1 syringe (1 mL) by deep intramuscular injection. All horses and ponies, not previously immunized, should receive an initial vaccination and a booster vaccination four weeks later. This should be followed by revaccination at six months and twelve months after the initial vaccination.

Thereafter, a booster should be given at twelve month intervals.

Because of possible interference by maternally derived antibodies, foals should ideally not be vaccinated before six months of age. If vaccination is intended before this age, foals should be tested for the presence of maternally derived antibodies, but foals should be at least 4 months of age before vaccination.

Equilis Equenza T Caution

1. Vaccinate only healthy animals. Diseased, stressed or parasitized animals may not respond adequately to vaccination and may not develop satisfactory immunity.

2. Use sterile injection equipment only.

3. The injection site should be clean to avoid contamination, which can result in local reactions at the injection site.

4. Follow directions carefully.

5. FOR VETERINARY USE ONLY.

6. In case of anaphylactic reaction, administer epinephrine.

Records

It is recommended that a record of vaccination be kept for each animal, indicating date of vaccination, lot number and date of expiration of the vaccine and name of the person doing the vaccination.

Packaging And Storage

10 x 1 mL (1 dose) pre-filled syringes. Refrigerate at 2-8°C (36-46°F). Do not freeze.

Manufactured by: Intervet International B.V., Boxmeer, The Netherlands

Distributed by: Intervet Canada Ltd., Whitby, ON L1N 9T5

099148A 0011.570.5165

099148A 5.03

Nac No.

12181651
INTERVET CANADA LTD.
250 WATER STREET, WHITBY, ON, L1N 9T5
Telephone:   905-430-9099
Order Desk:   866-NTERVET (866-683-7838)
Technical Assistance:   877-464-7616 or 800-268-4257
Fax:   905-430-3709
Toll-Free Fax:   888-498-4444
Website:   www.intervet.ca
Every effort has been made to ensure the accuracy of the Equilis Equenza T information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Equilis Equenza T product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-07-28

(web3)